Growth hormone treatment of rats with chronic diverting colostomy. Differential response on proximal functioning and distal atrophic colon

1994 ◽  
Vol 130 (5) ◽  
pp. 508-514 ◽  
Author(s):  
P Kissmeyer-Nielsen ◽  
H Christensen ◽  
S Laurberg

Kissmeyer-Nielsen P, Christensen H, Laurberg S. Growth hormone treatment of rats with chronic diverting colostomy. Differential response on proximal functioning and distal atrophic colon. Eur I Endocrinol 1994;130:508–14. ISSN 0804–4643 Diversion of colon from the fecal stream leads to profound intestinal atrophy. After diverting colostomy for 4 weeks, female rats were treated with biosynthetic human growth hormone (b-hGH; 2.0 mg.kg−1 body wt.day−1) in order to investigate whether b-hGH could reverse atrophic changes in distal colon, with special reference to changes in morphometric composition, collagen content and biomechanical properties. Biosynthetic hGH treatment for 28 days stimulated growth of the muscularis propria of the defunctioned, atrophic colon (p < 0.05), whereas the mucosal atrophy was unaffected by the treatment. In colon proximal to the colostomy, however, b-hGH increased the colonic wet weight (p < 0.01), defatted dry weight (p < 0.005) and the collagen content (p < 0.05). Morphometric analysis showed that the growth increase was localized to the mucosa and the muscularis propria. In conclusion, fecal diversion alters the response of b-hGH treatment and indicates that the trophic effect of growth hormone on colonic mucosa is dependent on fecal bulk passage, whereas the trophic effect on muscularis propria is fully retained when colon is deprived of luminal nutrients. Peter Kissmeyer-Nielsen, Surgical Research Unit, Department of Surgery L, Amtssygehuset, University Hospital of Aarhus, DK-8000 Aarhus C, Denmark

Diabetes ◽  
1993 ◽  
Vol 42 (7) ◽  
pp. 1082-1085 ◽  
Author(s):  
S. E. Kahn ◽  
F. F. Horber ◽  
R. L. Prigeon ◽  
M. W. Haymond ◽  
D. Porte

2021 ◽  
Author(s):  
Toshiaki Tanaka ◽  
Takahiro Sato ◽  
Akira Yuasa Mhwm ◽  
Takeshi Akiyama ◽  
Adeeb Tawseef

2021 ◽  
Vol 10 (15) ◽  
pp. 3250
Author(s):  
Karlijn Pellikaan ◽  
Anna G. W. Rosenberg ◽  
Kirsten Davidse ◽  
Anja A. Kattentidt-Mouravieva ◽  
Rogier Kersseboom ◽  
...  

Prader-Willi syndrome (PWS) is a complex hypothalamic disorder. Features of PWS include hyperphagia, hypotonia, intellectual disability, and pituitary hormone deficiencies. The combination of growth hormone treatment and multidisciplinary care (GHMDc) has greatly improved the health of children with PWS. Little is known about the effects of childhood GHMDc on health outcomes in adulthood. We retrospectively collected clinical data of 109 adults with PWS. Thirty-nine had received GHMDc during childhood and adolescence (GHMDc+ group) and sixty-three had never received growth hormone treatment (GHt) nor multidisciplinary care (GHMDc− group). Our systematic screening revealed fewer undetected health problems in the GHMDc+ group (10%) than in the GHMDc− group (84%). All health problems revealed in the GHMDc+ group had developed between the last visit to the paediatric and the first visit to the adult clinic and/or did not require treatment. Mean BMI and the prevalence of diabetes mellitus type 2 were significantly lower in the GHMDc+ group compared to the GHMDc− group. As all patients who received GHt were treated in a multidisciplinary setting, it is unknown which effects are the result of GHt and which are the result of multidisciplinary care. However, our data clearly show that the combination of both has beneficial effects. Therefore, we recommend continuing GHMDc after patients with PWS have reached adult age.


Sign in / Sign up

Export Citation Format

Share Document